Major Depressive Disorder Epidemiology Forecast

DelveInsight’s ‘Major depressive disorder (MDD) – Epidemiology Forecast – 2032’ report delivers an in-depth understanding of the historical and forecasted epidemiology of major depressive disorder (MDD) in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2019–2032

Major depressive disorder (MDD): Disease Understanding

Major depressive disorder (MDD) Overview

Major Depressive Disorder (MDD), also referred as depression, is a serious medical illness that disrupts a person’s mood, behavior, thought processes, apart from degrading the physical health. It should not be mistaken for the passing feelings of unhappiness that everyone experiences, nor should it be confused with the intense grief brought about by the death of a loved one. Sadness and grief are normal reactions to life stresses. With time, and usually without medical treatment, sadness and grief lift, and people go on with their lives. By contrast, without specialized medical treatment, depression often persists. But with effective treatment, a large majority of people improve significantly. In most instances, MDD is a recurrent, episodic illness. This means that a person who has been depressed once and has recovered is likely to have one or more episodes of depression in the future, often within 2 to 3 years. When depression is not treated, or is treated inappropriately, it is potentially fatal: nearly one in six people with severe, untreated depression commits suicide. However, seeking help and receiving an accurate diagnosis from a psychiatrist or other health care professional is a crucial and often decisive step toward recovery.

 

MDD is one form of depressive illness, or mood disorder. Other forms include bipolar disorder (manic-depressive illness) and dysthymia. In bipolar disorder, episodes of depression alternate with episodes of mania, a condition in which inappropriate or extreme “high” feelings may lead to dangerous, destructive behavior. Dysthymia involves symptoms similar to those of major depressive disorder. The symptoms are milder but longer lasting, and although they might not be disabling, they prevent a person from feeling good or 2 operating at “full steam.” Occasionally, a person with dysthymia may also have major depressive disorder, a condition referred to as double depression.

 

According to the World Health Organization (WHO), unipolar depression is one of the leading causes of disability- adjusted life year (DALY) and approximately 350 million people worldwide are said to suffer from this mental disorder. As described in the Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM- V), the hallmark of major depressive disorder is the occurrence of depressed mood (dysphoria) and loss of interest in activities that were rather pleasurable in the past (anhedonia) for a duration of at least two weeks. These symptoms must also be accompanied by at least four of the following manifestations such as changes in appetite or weight, sleep patterns, altered psychomotor activity, feelings of worthlessness or guilt, difficulty concentrating or making decisions and recurrent thoughts of death or suicidal ideation. Even though there are plenty of drugs developed for the management of depression, one of the challenges in dealing with this disease is that a significant portion of the patients taking antidepressants fail to attain full remission. Some patients also develop treatment resistant depression in which the patients fail to respond to the available drugs or other therapeutic approaches.

Major depressive disorder (MDD): Epidemiology

The Major depressive disorder (MDD) epidemiology division provides insights into the historical and current patient pool, along with the forecast trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends, along with assumptions undertaken.

 

Key Findings

The disease epidemiology covered in the report provides historical and forecasted major depressive disorder (MDD) epidemiology segmented as the 12-month Prevalent Cases of Major Depressive Disorder, Gender-specific Cases of Major Depressive Disorder, Severity Specific Cases of Major Depressive Disorder, and Relapse/Refractory Cases of Major Depressive Disorder. The report includes the prevalent scenario of major depressive disorder (MDD) in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019–2032.

Country-wise Major Depressive Disorder (MDD) Epidemiology

The epidemiology segment also provides the major depressive disorder (MDD) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

  • The total 12-month prevalent patient population of MDD in the 7MM countries was over 48 million cases in 2021.
  • As per the estimates, the United States had the highest 12-month prevalent patient population of MDD in 2021. Among the EU5 countries, Germany had the highest 12-month prevalent patient population of MDD with more than 7 million cases, followed by the UK in 2021. On the other hand, Spain had the lowest 12-month prevalent patient population of MDD with ~2 million cases in 2021.

Scope of the Report

  • Major depressive disorder report covers a detailed overview explaining its causes, symptoms and classification, pathophysiology, diagnosis, and treatment patterns.
  • Major Depressive Disorder Epidemiology Report and Model provide an overview of the risk factors and global trends of Major depressive disorder in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
  • The report provides insight into the historical and forecasted patient pool of major depressive disorder in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan.
  • The report helps recognize the growth opportunities in the 7MM concerning the patient population.
  • The report assesses the disease risk and burden and highlights the unmet needs of major depressive disorder.
  • The report provides the segmentation of the major depressive disorder epidemiology by 12-month prevalent cases of major depressive disorder in the 7MM.
  • The report provides the segmentation of the major depressive disorder epidemiology by gender-specific cases of major depressive disorder in the 7MM.
  • The report provides the segmentation of the major depressive disorder epidemiology by severity specific cases of major depressive disorder in the 7MM.
  • The report provides the segmentation of the major depressive disorder epidemiology by relapse/refractory cases of major depressive disorder in the 7MM.

Report Highlights

  • 11-year Forecast of major depressive disorder epidemiology
  • 7MM Coverage
  • 12-month prevalent cases of major depressive disorder
  • Gender-specific cases of major depressive disorder
  • Severity specific cases of major depressive disorder
  • Relapse/Refractory cases of major depressive disorder

KOL Views

We interview KOLs and obtain SME’s opinions through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the indications.

Key Questions Answered

  • What are the major factors that will drive the growth in the patient population in major depressive disorder during the forecast period (2019–2032)?
  • What are the key findings pertaining to the major depressive disorder epidemiology across 7MM, and which country will have the highest number of patients during the forecast period (2019–2032)?
  • What would be the total number of patients with major depressive disorder across the 7MM during the forecast period (2019–2032)?
  • Among the EU5 countries, which country will have the highest number of patients during the forecast period (2019–2032)?
  • At what CAGR is the patient population expected to grow in the 7MM forecast period (2019–2032)?
  • What are the disease risk, burdens, and unmet needs of major depressive disorder?
  • What are the currently available treatments for major depressive disorder?

Reasons to buy

Major Depressive Disorder (MDD) Epidemiology report will allow the user to:

  • Develop business strategies by understanding the trends shaping and driving the global major depressive disorder (MDD) market.
  • Quantify patient populations in the global major depressive disorder market to improve product design, pricing, and launch plans.
  • Understand the magnitude of the major depressive disorder (MDD) population by its 12-month prevalent cases.
  • Understand the magnitude of the major depressive disorder (MDD) population by its gender-specific cases.
  • Understand the magnitude of the major depressive disorder (MDD) population by its severity specific cases.
  • Understand the magnitude of the major depressive disorder (MDD) population by its relapse/refractory cases.
  • The Major Depressive Disorder (MDD) Epidemiology Report and Model were written and developed by Masters and PhD level epidemiologists
  • The Major Depressive Disorder (MDD) Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports the data presented in the report and showcases disease trends over an 11-year forecast period using reputable sources

Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

1. Key Insights

2. Report Introduction

3. Major Depressive Disorder Market Overview at a Glance

3.1. Market Share (%) Distribution of MDD in 2019

3.2. Market Share (%) Distribution of MDD in 2032

4. Executive Summary of Major Depressive Disorder

5. Disease Background and Overview

5.1. Introduction

5.2. Sign and Symptoms

5.3. Types

5.4. Causes

5.5. Pathophysiology of Depression

5.6. Genetic basis of MDD

5.7. Biomarkers

5.8. Diagnosis and severity

5.8.1. The Diagnostic and Statistical Manual of Mental Disorders (DSM)

5.8.2. DSM-IV-TR Criteria for MDD

5.8.3. DSM-V: Diagnostic Criteria

5.8.4. Differential Diagnosis

5.8.5. DSM-IV-TR Criteria for Major Depressive Disorder

5.8.6. Depression Rating Scale

5.8.7. Montgomery-Åsberg Depression Rating Scale (MADRS)

5.8.8. Depression Rating Scale (DRS)

6. Epidemiology and Patient Population

6.1. Key Findings

6.2. 7MM Total 12-month Prevalent Patient Population of Major Depressive Disorder

6.3. The United States

6.3.1. 12-month Prevalent Cases of Major Depressive Disorder in the US

6.3.2. Gender-specific Prevalence of Major Depressive Disorder in the US

6.3.3. Severity Specific Cases of Major Depressive Disorder in the US

6.3.4. Relapse/Refractory Cases of Major Depressive Disorder in the US

6.4. EU5

6.4.1. Total 12-month Prevalent Cases of Major Depressive Disorder in EU-5 Countries

6.4.2. Germany

6.4.3. Gender-specific Prevalence of Major Depressive Disorder in Germany

6.4.4. Severity Specific Cases of Major Depressive Disorder in Germany

6.4.5. Relapse/Refractory Cases of Major Depressive Disorder in Germany

6.4.6. France

6.4.7. Gender-specific Prevalence of Major Depressive Disorder in France

6.4.8. Severity Specific Cases of Major Depressive Disorder in France

6.4.9. Relapse/Refractory Cases of Major Depressive Disorder in France

6.4.10. Italy

6.4.11. Gender-specific Prevalence of Major Depressive Disorder in Italy

6.4.12. Severity Specific Cases of Major Depressive Disorder in Italy

6.4.13. Relapse/Refractory Cases of Major Depressive Disorder in Italy

6.4.14. Spain

6.4.15. Gender-specific Prevalence of Major Depressive Disorder in Spain

6.4.16. Severity Specific Cases of Major Depressive Disorder in Spain

6.4.17. Relapse/Refractory Cases of Major Depressive Disorder in Spain

6.4.18. The United Kingdom

6.4.19. Gender-specific Prevalence of Major Depressive Disorder in the UK

6.4.20. Severity Specific Cases of Major Depressive Disorder in the UK

6.4.21. Relapse/Refractory Cases of Major Depressive Disorder in the UK

6.5. Japan

6.5.1. 12-month Prevalent Cases of Major Depressive Disorder in Japan

6.5.2. Gender-specific Prevalence of Major Depressive Disorder in Japan

6.5.3. Severity Specific Cases of Major Depressive Disorder in Japan

6.5.4. Relapse/Refractory Cases of Major Depressive Disorder in Japan

7. Treatment and Management

7.1. American Psychiatric Association: Guideline on the Treatment of Patients with Major Depressive Disorder

7.2. Major Depressive Disorder Treatment Guidelines in the US and Europe

7.3. Guidelines in Spanish SHN for the Management of Major Depression in Adults

7.4. Major Depressive Disorder Treatment Guidelines in Japan

7.5. Major depressive disorder – Clinical practice review

7.6. Treatment Options for Adults

7.7. Treatment Options for Children and Adolescents

7.8. Treatment Options for Late-Life (Older Adults)

7.9. Algorithm for the Management of Major Depressive Disorder

7.10 Algorithm for the Management of Major Depressive Disorder

8. Organizations contributing towards MDD

9. Patient Journey

10. Case Report

11. SWOT Analysis

12. Unmet Needs

13. Market Access

14. Appendix

14.1. Bibliography

14.2. Report Methodology

15. DelveInsight Capabilities

16. Disclaimer

17. About DelveInsight

List of Tables

Table 1: Summary of Major Depressive Disorder, Market, Epidemiology, and Key Events (2019–2032)

Table 2: Assessing the severity of depression

Table 3: DSM-IV-TR diagnostic criteria - MDD

Table 4: DSM-IV-TR diagnostic criteria for MDD, Single episode

Table 5: DSM-IV-TR diagnostic criteria for MDD, Recurrent

Table 6: Selected DSM-IV-TR Major Depressive Episode Specifier

Table 7: Major depressive disorder diagnostic criteria according to DSM-V

Table 8: General Diagnostic Criteria of a Depressive episode according to ICD-10

Table 9: Severity Criteria of a Depressive episode according to ICD-10

Table 10: 12-month Prevalent Patient Population of MDD in the 7MM (2019–2032)

Table 11: 12-month Prevalent Cases of Major Depressive Disorder in the US (2019–2032)

Table 12: Gender-specific Prevalence of Major Depressive Disorder in the US (2019–2032)

Table 13: Severity Specific Cases of Major Depressive Disorder in the US (2019–2032)

Table 14: Relapse/Refractory Cases of Major Depressive Disorder in the US (2019–2032)

Table 15: 12-month Prevalent Cases of Major Depressive Disorder in EU-5 (2019–2032)

Table 16: Gender-specific Prevalence of Major Depressive Disorder in Germany (2019–2032)

Table 17: Severity Specific Cases of Major Depressive Disorder in Germany (2019–2032)

Table 18: Relapse/Refractory Cases of Major Depressive Disorder in Germany (2019–2032)

Table 19: Gender-specific Prevalence of Major Depressive Disorder in France (2019–2032)

Table 20: Severity Specific Cases of Major Depressive Disorder in France (2019–2032)

Table 21: Relapse/Refractory Cases of Major Depressive Disorder in France (2019–2032)

Table 22: Gender-specific Prevalence of Major Depressive Disorder in Italy (2019–2032)

Table 23: Severity Specific Cases of Major Depressive Disorder in Italy (2019–2032)

Table 24: Relapse/Refractory Cases of Major Depressive Disorder in Italy (2019–2032)

Table 25: Gender-specific Prevalence of Major Depressive Disorder in Spain (2019–2032)

Table 26: Severity Specific Cases of Major Depressive Disorder in Spain (2019–2032)

Table 27: Relapse/Refractory Cases of Major Depressive Disorder in Spain (2019–2032)

Table 28: Gender-specific Prevalence of Major Depressive Disorder in the UK (2019–2032)

Table 29: Severity Specific Cases of Major Depressive Disorder in the UK (2019–2032)

Table 30: Relapse/Refractory Cases of Major Depressive Disorder in the UK (2019–2032)

Table 31: 12-month Prevalent Cases of Major Depressive Disorder in Japan (2019–2032)

Table 32: Gender-specific Prevalence of Major Depressive Disorder in Japan (2019–2032)

Table 33: Severity Specific Cases of Major Depressive Disorder in Japan (2019–2032)

Table 34: Relapse/Refractory Cases of Major Depressive Disorder in Japan (2019–2032)

List of Figures

Figure 1: Structural and Functional Brain Abnormalities in Patients with Major Depressive Disorder

Figure 2: 12-month Prevalent Patient Population of MDD in the 7MM (2019–2032)

Figure 3: 12-month Prevalent Cases of Major Depressive Disorder in the US (2019–2032)

Figure 4: Gender-specific Prevalence of Major Depressive Disorder in the US (2019–2032)

Figure 5: Severity Specific Cases of Major Depressive Disorder in the US (2019–2032)

Figure 6: Relapse/Refractory Cases of Major Depressive Disorder in the US (2019–2032)

Figure 7: 12-month Prevalent Cases of Major Depressive Disorder in EU-5 countries (2019–2032)

Figure 8: Gender-specific Prevalence of Major Depressive Disorder in Germany (2019–2032)

Figure 9: Severity Specific Cases of Major Depressive Disorder in Germany (2019–2032)

Figure 10: Relapse/Refractory Cases of Major Depressive Disorder in Germany (2019–2032)

Figure 11: Gender-specific Prevalence of Major Depressive Disorder in France (2019–2032)

Figure 12: Severity Specific Cases of Major Depressive Disorder in France (2019–2032)

Figure 13: Relapse/Refractory Cases of Major Depressive Disorder in France (2019–2032)

Figure 14: Gender-specific Prevalence of Major Depressive Disorder in Italy (2019–2032)

Figure 15: Severity Specific Cases of Major Depressive Disorder in Italy (2019–2032)

Figure 16: Relapse/Refractory Cases of Major Depressive Disorder in Italy (2019–2032)

Figure 17: Gender-specific Prevalence of Major Depressive Disorder in Spain (2019–2032)

Figure 18: Severity Specific Cases of Major Depressive Disorder in Spain (2019–2032)

Figure 19: Relapse/Refractory Cases of Major Depressive Disorder in Spain (2019–2032)

Figure 20: Gender-specific Prevalence of Major Depressive Disorder in the UK (2019–2032)

Figure 21: Severity Specific Cases of Major Depressive Disorder in the UK (2019–2032)

Figure 22: Relapse/Refractory Cases of Major Depressive Disorder in the UK (2019–2032)

Figure 23: 12-month Prevalent Cases of Major Depressive Disorder in Japan (2019–2032)

Figure 24: Gender-specific Prevalence of Major Depressive Disorder in Japan (2019–2032)

Figure 25: Severity Specific Cases of Major Depressive Disorder in Japan (2019–2032)

Figure 26: Relapse/Refractory Cases of Major Depressive Disorder in Japan (2019–2032)

Forward to Friend

Need A Quote